DMCA
REVIEW The Janus face of dendritic cells in cancer
| Citations: | 2 - 0 self |
BibTeX
@MISC{Chaput_reviewthe,
author = {N Chaput and R Conforti and S Viaud and A Spatz and L Zitvogel},
title = {REVIEW The Janus face of dendritic cells in cancer},
year = {}
}
Share
 |
 |
 |
 |
||
OpenURL
Abstract
On the basis of experimental models and some human data, we can assume that tumor outgrowth results from the balance between immunosurveillance (the extrinsic tumor suppressor mechanisms) and immunosubversion dictated by transformed cells and/or the corrupted surrounding microenvironment. Cancer immunosurveil-lance relies mainly upon conventional lymphocytes exerting either lytic or secretory functions, whereas immunosubversion results from the activity of regulatory T or suppressor myeloid cells and soluble mediators. Although specific tools to target or ablate dendritic cells (DCs) became only recently available, accumulating evidence points to the critical role of the specialized DC system in dictating most of the conventional and regulatory functions of tumor-specific T lymphocytes. Although DC can be harnessed to silence tumor develop-ment, tumors in turn can exploit DC to evade immunity. Indeed, DCs harbor defects in their differentiation and stimulatory functions in cancer-bearing hosts and can actively promote T-cell tolerance to self-tumor antigens. In this review, we will focus on the dual role of DC during tumor progression and discuss pharmacoimmunological strategies to harness DC against cancer.
Keyphrases
dendritic cell janus face tumor progression cancer-bearing host dc system critical role regulatory function specific tool cancer immunosurveil-lance relies tumor develop-ment extrinsic tumor suppressor mechanism human data stimulatory function discus pharmacoimmunological strategy whereas immunosubversion result dc harbor defect corrupted surrounding microenvironment tumor-specific lymphocyte t-cell tolerance soluble mediator conventional lymphocyte dual role secretory function transformed cell suppressor myeloid cell self-tumor antigen evidence point experimental model
